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The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the 
number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in 
insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a posi-
tion statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position state-
ment were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the 
Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including ex-
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tended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of 
acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrep-
ancies among the expert opinions were found, the experts voted to determine the recommended approach.
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INTRODUCTION
Acromegaly is a chronic disease caused by hypersecretion of 
growth hormone (GH), and GH-secreting pituitary tumors are 
found in 95% of acromegaly patients [1]. Acromegaly is a rare 
disease with an annual incidence of 3.3 cases per million persons, 
and estimated prevalence of 40 to 130 per million persons [2]. In 
Korea, the annual incidence was 3.9 cases per million persons in 
2007, and the prevalence was 27.0 cases per million persons [3]. 
The primary treatment for patients with acromegaly caused by 
pituitary tumors excessively secreting GH is surgery [4] to re-
move the tumor through a trans-sphenoidal adenomectomy. 
However, the success rate of surgical treatment varies depending 
on the size of tumor, extent of tumor invasion and the proficiency 
of the neurosurgeon performing the surgery [5-8]. Approximately 
70% of the patients with pituitary microadenomas are able to 
maintain their serum GH and insulin-like growth factor-1 (IGF-
1) concentrations within the normal range after surgery [9]; how-
ever, such curative effects can be expected for only 50% of the 
patients with pituitary macroadenomas [10]. Postoperative medi-
cal treatment may be initiated when serum GH concentrations 
are not reduced to 1 μg/L or lower based on the 75-g oral glucose 
tolerance test 3 months after surgery, indicating the likely pres-
ence of residual tumor [4]. Medical treatment options for these 
patients include somatostatin analogues (octreotide, lanreotide, 
and pasireotide), GH receptor antagonists (pegvisomant), or oral 
dopamine agonists (cabergoline). The treatment goals for acro-
megaly are to reduce the tumor size and to maintain GH and 
IGF-1 within normal ranges as well as to improve the clinical 
symptoms and signs of acromegaly [1]. When surgical treatments 
are unavailable or are refused by patients, medical treatments 
may be considered as primary therapy [1]. 
The Korean Endocrine Society (KES) published clinical prac-
tice guidelines for the treatment of acromegaly in 2011. Since 
then, the number of acromegaly cases, publications on studies 
addressing medical treatment of acromegaly, and demands for 
improvements in insurance coverage have been dramatically in-
creasing. In 2017, the KES Committee of Health Insurance de-
cided to publish a position statement regarding the use of soma-
tostatin analogues in acromegaly. Accordingly, consensus opin-
ions for the position statement were collected after intensive re-
view of the relevant literature and discussions among experts 
affiliated with the KES and the Korean Neuroendocrine Study 
Group. In this position statement, the recommended approach is 
based on the expert opinions in case of insufficient clinical evi-
dence, and where discrepancies among the expert opinions were 
found, the experts voted to determine the recommended ap-
proach. The recommendation levels were defined depending 
upon strength of evidence as shown in Table 1.
SUMMARY 
Indication and treatment goals of using somatostatin 
analogues in acromegaly
(1)  Medical treatment using somatostatin analogues in acro-
megaly may be initiated when serum GH concentrations are 
not reduced to 1 μg/L or lower based on the 75-g oral glu-
cose tolerance test 3 months after surgery. Treatment goals 
are to reduce the tumor size, to maintain GH and IGF-1 
within normal ranges and as well as to improve the clinical 
symptoms and signs (A).
Initial dose and dose adjustment of somatostatin analogues
(1)  The initial dose of octreotide long-acting release (LAR) is 
20 mg, administered by intramuscular injection at 4-week 
intervals. If octreotide LAR fails to suppress serum GH con-
centrations below 2.5 μg/L after the first 3 months of use, the 
dose may be increased to 30 mg every 4 weeks. The maxi-
mum dose is 40 mg every 4 weeks. If serum GH concentra-
tions remained suppressed below 1 μg/L after administering 
20 mg octreotide LAR every 4 weeks for 3 months or lon-
ger, and the presenting symptoms and signs of disease are 
alleviated, the dose may be reduced to 10 mg every 4 weeks 
(B). 
(2)  Lanreotide autogel (ATG) can be administered at an initial 
dose of 60, 90, or 120 mg every 4 weeks. If serum GH con-
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centrations are not reduced below 2.5 μg/L after administra-
tion of 60 or 90 mg every 4 weeks for 3 months, the dose 
may be gradually increased to a maximum of 120 mg every 
4 weeks (B).
(3)  The initial dose of pasireotide LAR is 40 mg every 4 weeks. 
If serum GH concentrations are not suppressed after the first 
3 months of treatment, the dose may be increased to 60 mg 
every 4 weeks (B).
Switching somatostatin analogues 
(1)  When one somatostatin analogue is switched to another in 
order to improve the biochemical profile and reduce adverse 
effects, the new drug should be administered at the initial 
dose outlined in Section 2, above (E).
(2)  When switching from octreotide LAR to lanreotide ATG, 
lanreotide ATG can be administered at 60, 90, or 120 mg re-
gardless of the previous dosage of octreotide LAR. When 
switching from lanreotide ATG to octreotide LAR, the initial 
dose of octreotide LAR should be 20 mg every 4 weeks (E).
Extended dose interval for lanreotide ATG
(1)  For patients whose GH concentrations have been reduced 
below 2.5 μg/L and clinical symptoms are controlled when 
administered octreotide LAR or lanreotide ATG for 3 
months or longer, the dose interval may be extended to 8 
weeks by switching to 120 mg of lanreotide ATG regardless 
of the dose of somatostatin analogue previously adminis-
tered (C).
Preoperative use of somatostatin analogues
(1)  The routine use of preoperative somatostatin analogues prior 
to surgical excision of pituitary adenomas is not recom-
mended; however, when surgical treatment is not available 
or refused, medical treatment may be considered as primary 
therapy (A).
Special circumstances
(1)  Metformin is the preferred treatment for patients who be-
come hyperglycemic during somatostatin analogue therapy, 
especially with pasireotide LAR. Dipeptidyl-peptidase-4 in-
hibitors or glucagon-like peptide-1 receptor agonists are also 
recommended (E).
(2)  Use of contraception when somatostatin analogues are ad-
ministered and discontinuation of somatostatin analogues if 
pregnancy is considered are recommended (E).
SOMATOSTATIN AND THE SOMATOSTATIN 
RECEPTOR
The secretion of GH from the anterior pituitary gland is inhibit-
ed by many factors including somatostatin from the hypothala-
mus [11]. Somatostatin is also secreted from the gastrointestinal 
tract: somatostatin comprised of 14 amino acids is secreted from 
hypothalamus, and those consisting of 28 amino acids from 
δ-cells at the duodenum and jejunum [12]. Somatostatin exerts 
inhibitory effects on all of hormone secretions from the pituitary, 
pancreas, gut, and gallbladder by binding to somatostatin recep-
tors (SSTR). Five subtypes of the SSTR have been identified 
[12]: GH-secreting pituitary tumor cells mainly express SSTR 
type 2 (SSTR2, >95%) and type 5 receptors (SSTR5, >85%) [13], 
while type 3 (SSTR3) and type 1 receptors (SSTR1) are each ex-
pressed on 40% of GH-secreting tumors, and type 4 receptors 
(SSTR4) are rarely expressed [14]. In addition, SSTR has been 
confirmed to be expressed within the central nervous system 
Table 1. Definition of Recommendation Levels
Recommendation level Definition
A When there is a clear rationale for the recommendations: 
When manifold randomized controlled trials that can be generalized because they have sufficient test or meta-analysis  
results support a recommendation
B When there is a reliable basis for the recommendations: 
When reasonable grounds support this through well-performed cohort studies or patient—control group studies
C When there is a possible basis for the recommendations: 
When relevant grounds are seen through randomized clinical studies or case reports and observational studies carried out 
in a small institution, despite their inherent unreliability
E Expert recommendations: 
There is no basis to support the recommendations, but they are supported by expert opinion or expert clinical experience
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and gastrointestinal tract, and on inflammatory, immune, and 
endocrine cells [15]. 
SOMATOSTATIN ANALOGUES
Since the half-life of secreted endogenous somatostatin is only 3 
to 5 minutes in vivo, persistent intravenous administration is re-
quired in order to maintain therapeutic levels. In addition, the 
use of endogenous somatostatin may be limited by potential in-
duction of rebound secretion of GH, insulin and glucagon fol-
lowing infusion [16]. As a result, somatostatin analogues with 
extended half-lives, such as octreotide and lanreotide, have been 
developed [17,18]. Both analogues were developed to lengthen 
their half-lives while maintain the β-turn structure (tetrapeptide 
Phe-Trp-Lys-Thr) and the disulfide bridge connecting amino ac-
ids (cysteine) at position 3 and 14 of endogenous somatostatin, 
which plays a critical role in the functions of somatostatin [12].
Octreotide is administered by subcutaneous or intravenous in-
jection. The affinity of octreotide for SSTR2 is 45 times greater 
than that of endogenous somatostatin (Kd=0.4 pM). The initial 
dose is 100 to 250 μg with every 8 hours; the dose may be in-
creased to 1.5 mg/day [19]. Its peak plasma concentrations are 
achieved 40 minutes following administration, and the half-life 
is approximately 2 hours [1]. While the half-life of octreotide is 
longer than that of endogenous somatostatin, it must still be ad-
ministered several times a day, which led to the development of 
the octreotide LAR formulation, in which octreotide is mixed 
with a diluent (carboxymethylcellulose sodium, mannitol, water) 
and microspheres of biodegradable glucose polymer [12]. Oc-
treotide LAR is administered by intramuscular injection, and 
maximum plasma concentrations are achieved within 1 hour of 
administration, possibly as a result of drug absorbed to the carri-
er microspheres [20]. Octreotide LAR is released in a biphasic 
manner, such that the plasma concentration declines within 12 
hours of administration, remains at sub-therapeutic levels for 
about 7 days, and then increases to reach its peak concentration 
on day 14 post-injection [21]. Since plasma concentrations re-
main elevated for about 35 to 60 days and decrease gradually, 
octreotide LAR is administered at intervals of 4 weeks, and plas-
ma concentrations reach steady state after three injections [20]. 
Lanreotide with sustained-release (SR) type is another soma-
tostatin analogue formulated as a biodegradable lactide/gly-
colide copolymer with high affinity for SSTR2 and a half-life of 
approximately 5 days. Lanreotide SR is administered through 
intramuscular injection at a dose of 30 or 60 mg every 7 to 14 
days [1]. The lanreotide ATG formulation consists of a supersat-
urated aqueous solution prepared in a prefilled syringe, which 
extends the dosing interval to 4 weeks with deep subcutaneous 
injection [22]. Its half-life is approximately 23 to 29 days with 
reaching its steady-state after four injections [1]. 
Based on the previous studies reporting the expression of 
SSTR5 in tumor cells of GH-producing pituitary adenoma and 
significant relationships between SSTR5 expression and disease 
activity in GH-secreting pituitary tumors [23,24], the second 
generation somatostatin analogue with greater affinity for 
SSTR5 and other SSTR subtypes, named pasireotide, was de-
veloped. Pasireotide is a cyclohexapeptide with a molecular 
weight of 1,047 Da, and the chemical formula of [(2-aminoeth-
yl)aminocarbonyloxy]-L-proline, phenylglycine, and tyrosine 
(benzyl) [25]. Pasireotide has 40-, 30- and 5-fold greater bind-
ing affinity for SSTR5, SSTR1, and SSTR3, respectively, than 
octreotide or lanreotide, and approximately 2.5 times lower af-
finity for SSTR2 [26]. Pasireotide LAR with its extended injec-
tion interval was developed by using biodegradable polymers 
similar to those included in the octreotide LAR [12]. Plasma 
concentrations reach an initial maximum 24 hours after admin-
istration, and the concentration declines for the next 7 days, and 
then increase again to reach a second maximum on day 21 post-
injection [27]. Similar to octreotide LAR, plasma pasireotide 
concentrations reach steady state after three injections when ad-
ministered at 4-week intervals. 
Somatostatin analogues result in inhibition of GH secretion 
and cell division of somatotropes in the pituitary gland. They 
also play a role to suppress IGF-1 production in the liver [1,28]. 
It has been proposed that somatostatin analogues may reduce 
tumor size through the apoptosis by induction of ZAC1 protein 
expression [12], or reduction of the Ki67 index which leads to 
the decreased cell cycling of GH-secreting pituitary tumor cells 
[29]. Since the publication of the first case report of normaliza-
tion of GH and IGF-1 levels and symptoms in acromegaly pa-
tients treated with octreotide 30 years ago [30], the reported 
control rate by using somatostatin analogues vary widely de-
pending on the study conditions. When octreotide LAR was ad-
ministered at the recommended dose (20 to 30 mg/month), it 
was reported that IGF-1 and GH were reduced to normal ranges 
(<2.5 μg/L) among 38% to 85% and 33% to 75% of patients, 
respectively [31]; similarly, in patients administered lanreotide 
ATG, GH, and IGF-1 levels were lowered to normal ranges in 
39% to 80% and 38% to 80% of patients, respectively [32]. 
Treatment with octreotide LAR for 48 weeks resulted in signifi-
cant reductions of tumor size (>20%) in approximately 75% of 
patients [33], while lanreotide ATG significantly reduced tumor 
Somatostatin Analogues in Acromegaly
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size (>20%) among 54% of patients after 12 weeks [34]. Lan-
reotide ATG significantly reduced serum GH and IGF-1 con-
centrations following 6 to 12 months of treatment, according to 
a retrospective analysis of acromegaly patients in Korea [35]. 
According to the study with newly diagnosed patients, treat-
ment with pasireotide LAR for 12 months resulted in a greater 
proportion of patients achieving the treatment goals (GH <2.5 
μg/L and IGF-1 within normal range) than treatment with oc-
treotide LAR (31.3% vs. 19.2%) [36]. Subgroup analyses of pa-
tients who underwent surgery before medical treatment also 
produced similar results [36]. A follow-up study found that 
48.6% and 45.7% of patients who continued to receive either 
pasireotide LAR or octreotide LAR, respectively, achieved the 
treatment goals for up to 12 additional months [37]. Among pa-
tients who failed to meet the treatment goal after 12 months and 
were switched to either pasireotide LAR or octreotide LAR for 
up to 26 additional months, 17.3% of those switched from oc-
treotide LAR to pasireotide LAR achieved biochemical control, 
whereas none of the patients switched from pasireotide LAR to 
octreotide LAR achieved biochemical control [38]. In addition, 
the pasireotide versus continued treatment with octreotide or 
lanreotide in patients with inadequately controlled acromegaly 
(PAOLA) study, which investigated the effects of pasireotide 
LAR in patients who failed to meet the treatment goals with ei-
ther octreotide LAR or lanreotide ATG, reported that approxi-
mately 20% of patients who were switched to pasireotide LAR 
60 mg met the treatment goals [39].
INITIAL DOSE AND DOSE ADJUSTMENT 
DURING SOMATOSTATIN ANALOGUE 
TREATMENT
The initial dose of octreotide LAR is 20 mg, which must be ad-
ministered by intramuscular injection at 4-week intervals. If oc-
treotide LAR fails to reduce serum GH levels below 2.5 μg/L 
after the first 3 months of treatment, the dose may be increased 
to 30 mg every 4 weeks. The maximum dose is 40 mg every 4 
weeks (Fig. 1). Although it has been recently reported that the 
mortality rate of patients with acromegaly is similar to that of 
the general population when GH is reduced below 1.0 μg/L 
[40], this position statement employs a cut-off GH level of 2.5 
μg/L for the changes of drugs and their doses. It is because the 
accuracy and standardization of the GH assay kits currently 
available have not yet been established. Moreover, it is recom-
mended that hypersecretion of GH and disease activity of acro-
megaly not be diagnosed solely based upon serum IGF-1 levels 
[41,42]: IGF-1 secretion can be affected by various factors other 
than acromegaly, and data on the normal range of IGF-1 con-
centrations in the Korean population are lacking [41]. Thus, this 
position statement does not include the IGF-1 level as a criteri-
on to change the drugs and their doses. Once data regarding se-
rum IGF-1 levels in the Korean population become available, 
IGF-1 will be included in future revisions of this position state-
ment. When the GH level remains suppressed below 1 μg/L af-
ter using 20 mg of octreotide LAR every 4 weeks for 3 months 
or longer and symptoms and signs of excessive GH are alleviat-
ed, the dose can be reduced to 10 mg every 4 weeks. The pa-
tient’s biochemical parameters, clinical signs, and symptoms 
should be assessed on a regular basis during somatostatin ana-
logue treatment (expert opinion).
The initial dose of lanreotide ATG is 60, 90, or 120 mg every 
4 weeks. If serum GH levels are not reduced to 2.5 μg/L or less 
after using 60 or 90 mg every 4 weeks for 3 months, the dose 
may be gradually increased to a maximum of 120 mg every 4 
weeks (Fig. 1). When the GH levels are found to remain sup-
pressed within normal range, the dose may be reduced to 60 mg 
every 4 weeks, or the 120 mg dose be selected with the dose in-
terval extended to 6 to 8 weeks (refer to the paragraph below for 
more detailed explanation); in either case, patient symptoms 
and biochemical parameters should be monitored to verify the 
continued adequacy of treatment (expert opinion). 
The initial dose of pasireotide LAR is 40 mg every 4 weeks. 
If serum GH levels are not suppressed after the first 3 months, 
the dose may be increased to 60 mg every 4 weeks.
SWITCHING SOMATOSTATIN ANALOGUES 
There is no head-to-head study which has directly compared the 
therapeutic effects of octreotide LAR and lanreotide ATG dur-
ing treatment of patients with acromegaly. However, a number 
of small-scale studies have reported that both therapeutic agents 
produced similar effects on the improvement of biochemical 
parameters and reduction of tumor size [43]. Andries et al. [44] 
reported that both octreotide LAR and lanreotide ATG had al-
most identical effects on clinical improvement of symptoms and 
the GH and IGF-1 levels in patients with acromegaly after 
crossover administration of 10 mg of octreotide LAR and 60 
mg of lanreotide ATG, 20 mg of octreotide LAR and 90 mg of 
lanreotide ATG, and 30 mg of octreotide LAR and 120 mg of 
lanreotide ATG. In addition, this study found octreotide LAR 
and lanreotide ATG did not have common adverse effects [44], 
and it may therefore be beneficial to switch to another soma-
Chin SO, et al.
58 www.e-enm.org Copyright © 2019 Korean Endocrine Society
tostatin analogue when one fails to achieve the treatment goals 
or shows certain adverse effects. In a retrospective study of the 
effects of those two agents among Korean patients with acro-
megaly, there was no significant difference with respect to their 
therapeutic effects [45].
When one somatostatin analogue is switched to another in or-
der to improve biochemical control and reduce adverse effects, 
the new somatostatin analogue should be administered at the 
initial doses outlined above (Fig. 2). When switching from oc-
treotide LAR to lanreotide ATG, lanreotide ATG can be admin-
istered at either 60, 90, or 120 mg regardless of the previous 
dose of octreotide LAR; however, when switching from lanreo-
tide ATG to octreotide LAR, the initial dose of octreotide LAR 
should be 20 mg every 4 weeks. In either situation, serum GH 
levels should be measured regularly for the first 3 months, and 
if GH levels are not reduced below 2.5 μg/L, the dose may be 
increased (expert opinion). When GH secretion is not effective-
ly suppressed after at least 6 months of treatment at the maxi-
mum dose of octreotide LAR or lanreotide ATG, the drug may 
be switched to pasireotide LAR.
EXTENDED DOSE INTERVAL FOR 
LANREOTIDE ATG
The clinical practice guideline for acromegaly published by the 
Endocrine Society indicates the dose interval may be extended 
when the treatment goals are achieved with low-dose soma-
tostatin analogues [4,46]. The Lanreotide Extended ATG Dura-
tion (LEAD) study found therapeutic effects were maintained in 
patients who showed stable disease activity after more than 6 
months of treatment with octreotide LAR at 10 or 20 mg every 
4 weeks after switching them to lanreotide ATG 120 mg with 
the dose interval extended to 6 or 8 weeks [47]. Moreover, the 
extended dose interval (EDI) resulted in the improvement of pa-
tients’ adherence to treatment by less frequent dosing and re-
duced drug costs [47]. In a Polish multicenter observational 
study (the Lanro study), treatment costs were reduced when the 
dose interval was extended to 8 weeks for patients administered 
120 mg of lanreotide ATG [48]. Based on these findings, lanreo-
tide ATG is the only somatostatin analogue of which the exten-
Fig. 1. Initial dose and up-/down-titration of octreotide long-acting release (LAR) and lanreotide autogel (ATG) in patients with acromegaly. 
SSA, somatostatin analogues; OCT, octreotide; LAN, lanreotide; GH, growth hormone.
Fig. 2. Switching between octreotide long-acting release (LAR) 
and lanreotide autogel (ATG) during the medical treatment of acro-
megaly.
Medication (SSA)
Octreotide
OCT LAR 20 mg LAN ATG 90 mg
ATG 60 mg
LAN ATG 60 mg
LAR 10 mg
LAR 20 mg
LAR 30 mg
LAR 40 mg ATG 120 mg
ATG 90 mg
LAN ATG 120 mg
Follow-up 
after 3 mo
Follow-up 
after 3 mo
Maintain dose
GH 1.0−2.5 μg/L
Maintain dose
GH 1.0−2.5 μg/L
Reduce dose
GH <1 μg/L
Reduce dose
GH <1 μg/L
Increase dose
GH >2.5 μg/L
Increase dose
GH >2.5 μg/L
Lanreotide
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sion of the dose interval has been approved for medical treat-
ment of acromegaly [47].
Therefore, for patients whose serum GH concentration is be-
low 2.5 μg/L and clinical symptoms are sufficiently well con-
trolled with octreotide LAR or lanreotide ATG for 3 months or 
longer, their dose interval may be extended to 8 weeks by 
switching to lanreotide ATG 120 mg regardless of the dose of 
somatostatin analogues previously prescribed (expert opinion). 
The patient’s biochemical parameters, clinical signs and symp-
toms should be assessed on a regular basis during the use of 
lanreotide ATG with EDI (expert opinion).
PREOPERATIVE USE OF SOMATOSTATIN 
ANALOGUES
The results of the Preoperative Octreotide Treatment of Acro-
megaly (POTA) study demonstrated that patients with macroad-
enomas showed significantly greater reduction of serum IGF-1 
concentrations when receiving preoperative octreotide LAR 
treatment than patients who initially underwent surgical treat-
ments [49]; however, in the follow-up study which investigated 
these patients for another 5 years, there were no significant dif-
ferences between the outcomes of the two groups [50]. Thus, 
the guideline prepared by the Endocrine Society in 2014 does 
not recommend the routine use of preoperative somatostatin an-
alogues prior to surgical removal of pituitary adenoma for pa-
tients with acromegaly [4]. Nonetheless, when surgical treat-
ment is not available or refused, medical treatment may be con-
sidered the first-line treatment [1].
SPECIAL CIRCUMSTANCES
It has been reported that the adverse effects of somatostatin ana-
logues may be associated with its inhibition of peristalsis and of 
pancreatic and gastrointestinal peptide secretion. The adverse 
effects of somatostatin analogues include nausea, diarrhea, ab-
dominal pain, gastrointestinal paralysis, biliary sludge, and gall-
stones, but in most cases are mild and can be mitigated by re-
ducing the dose or ceasing administration of the drug [16]. 
There is also a report of a small number of patients experiencing 
bradycardia while receiving somatostatin analogs [19]. It has 
been reported that SSTR2, a major binding receptor of octreo-
tide or lanreotide, is also expressed in pancreatic α-cells [51], 
and somatostatin analogs do not significantly affect the secre-
tion of insulin in pancreatic β-cells, and rarely results in worsen-
ing of glucose control. There are a number of case reports indi-
cating glucose control improved as excessive secretion of GH 
and IGF-1 was resolved [52,53]. On the other hand, it was 
shown that patients administered pasireotide LAR were more 
likely to experience hyperglycemia or to develop diabetes when 
compared with those treated with octreotide LAR [36]. Unlike 
SSTR2 in α-cells, pancreatic β-cells and intestinal L-cells se-
creting glucagon-like peptide 1 (GLP-1) express SSTR5 to 
which pasireotide binds with high affinity [16,54]. Therefore, 
insulin secretion was found to be reduced by pasireotide, possi-
bly leading to the deterioration of glucose control. However, in-
sulin sensitivity was not affected [55]. Metformin is the pre-
ferred treatment for patients who become hyperglycemic during 
somatostatin analogue therapy; dipeptidyl-peptidase-4 inhibi-
tors or GLP-1 receptor agonists are also recommended [56].
As for confirmed pregnancy during the use of somatostatin 
analogues in patients with acromegaly, there have been 50 cases 
reported with treatment using somatostatin analogues at the 
time of conception but no malformations have been found in 
their children [4]. However, it is of note that octreotide can bind 
to SSTR in the placenta and cross the placenta [57], possibly af-
fecting the fetal development. Reduced blood flow in uterine ar-
tery when treated with short-acting octreotide [57] and intra-
uterine growth retardation after using a lower dose of octreotide 
LAR [58] have been reported. Due to the limited data available 
regarding the safety, it is recommended to use contraception 
when these drugs are administered and to discontinue soma-
tostatin analogues if pregnancy is considered [4]. Considering 
the prolonged nature of the disease course, interruption of medi-
cal therapy using somatostatin analogues for 9 to 12 months in 
patients with acromegaly should not have adverse effects on the 
long-term outcome [4].
CONCLUSIONS 
Somatostatin analogues may be used when complete recovery 
cannot be achieved by surgical excision of GH-secreting pitu-
itary adenomas or the patient declines surgery. This position 
statement is established based on the consensus of opinion 
among experts and evidence from published data regarding the 
use of somatostatin analogues in patients with acromegaly. 
However, this position statement cannot be considered as com-
plete, given the clinical characteristics of acromegaly and the 
absence of large-scale clinical data in Korea; at this time, the 
clinical judgement of the physician should take precedence over 
this statement. This position statement will be revised as needed 
when additional data for Korean patients become available.
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